Scientific publications (peer reviewed)
29) Rana R, Manoharan J, Elwakiel A, Zimmermann S, Lindquist JA, Gupta D, Al-Dabet MM, Gadi I, Fallmann J, Singh K, Gupta A, Biemann R, Brandt S, Alo B, Kluge P, Garde R, Lamers C, Shahzad K, Künze G, Kohli S, Mertens PR, Isermann B. Glomerular-tubular crosstalk via cold shock Y-box binding protein-1 in the kidney. Kidney Int. 2024 Jan;105(1):65-83. doi: 10.1016/j.kint.2023.09.014. Epub 2023 Sep 28.
28) Golomingi M, Kohler J, Lamers C, Pouw RB, Ricklin D, Dobó J, Gál P, Pál G, Kiss B, Dopler A, Schmidt CQ, Hardy ET, Lam W, Schroeder V. Complement inhibition can decrease the haemostatic response in a microvascular bleeding model at multiple levels. Front Immunol. 2023 Sep 13;14:1226832. doi: 10.3389/fimmu.2023.1226832. eCollection 2023.
27) C. Lamers, D. Ricklin, J.D. Lambris. Complement-targeted therapeutics: An emerging field enabled by academic drug discovery. Am J Hematol. 2023, May;98 Suppl 4:S82-S89. doi: 10.1002/ajh.26875.
26) C. Bechtler, S. Koutsogiannaki, E. Umnyakova, A. Hamid, A. Gautam, Y. Sarigiannis, R.B. Pouw, C. Lamers, S. Rabbani, C.Q. Schmidt, J.D. Lambris, D. Ricklin. Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6. Acta Biomater. 2022 Nov 1:S1742-7061(22)00712-7. doi: 10.1016/j.actbio.2022.10.055.
25) C. Lamers, X. Xue, M. Smieško, H. van Son, B. Wagner, N. Berger, G. Sfyroera, P. Gros, J.D. Lambris, D. Ricklin. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Nat Commun. 2022 Sep 20;13(1):5519. doi: 10.1038/s41467-022-33003-7.
24) C. Lamers. Overcoming the shortcomings of peptide-based therapeutics. Future Drug Discovery 2022, 4 (2). doi.org/10.4155/fdd-2022-0005.
23) C. Lamers, D. Mastellos, D. Ricklin, J.D. Lambris. Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends Pharmacol Sci. 2022 doi: 10.1016/j.tips.2022.01.004.
22) C. Bechtler, C. Lamers. Macrocyclization strategies for cyclic peptides and peptidomimetics. RSC Medicinal Chemistry 2021. RSC Med Chem. 2021 Jun 29;12(8):1325-1351. Part of the themed collection “Emerging Investigators”
21) C. Lamers*, CJ. Plüss, D. Ricklin. The Promiscuous Profile of Complement Receptor 3 in Ligand Binding, Immune Modulation, and Pathophysiology. Frontiers in Immunol. 2021 Apr 29;12:662164. *corresponding author
20) V. Carle, Y.Wu, R. Mukherjee, XD. Kong, C. Rogg, Q. Laurent, E. Cecere, C. Villequey, MS. Konakalla, T. Maric, C. Lamers, C. Díaz-Perlas, K. Butler, J. Goto, B. Stegmayr, C. Heinis. Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation. J Med Chem. 2021 May 27;64(10):6802-6813.
Wilbs J, Kong XD, Middendorp SJ, Prince R, Cooke A, Demarest CT, Abdelhafez MM, Roberts K, Umei N, Gonschorek P, Lamers C, Deyle K, Rieben R, Cook KE, Angelillo-Scherrer A, Heinis C.
Nat. commun. 2020 Aug 4;11(1):3890.
18) CHAPTER 3: Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators
Lamers C, Merk D
Anti-fibrotic Drug Discovery, RCS 2020 Mar
17) Molecular tuning of farnesoid X receptor partal agonism.
Merk D, Sreeramulu S, Kudlinzki D, Saxena K, Linhard V, Gande SL, Hiller F, Lamers C, Nilsson E, Aagaard A, Wissler L, Dekker N, Bamberg K, Schubert-Zsilavecz M, Schwalbe H.
Nat. commun. 2019 Jul 2;10(1):2915.
16) Nonacidic Farnesoid X Receptor Modulators.
Flesch D, Cheung SY, Schmidt J, Gabler M, Heitel P, Kramer J, Kaiser A, Hartmann M, Lindner M, Lüddens-Dämgen K, Heering J, Lamers C, Lüddens H, Wurglics M, Proschak E, Schubert-Zsilavecz M, Merk D.
J Med Chem. 2017 Aug 24;60(16):7199-7205.
Blöcher R, Lamers C, Wittmann SK, Merk D, Hartmann M, Weizel L, Diehl O, Brüggerhoff A, Boß M, Kaiser A, Schader T, Göbel T, Grundmann M, Angioni C, Heering J, Geisslinger G, Wurglics M, Kostenis E, Brüne B, Steinhilber D, Schubert-Zsilavecz M, Kahnt AS, Proschak E.
J Med Chem. 2016 Jan 14;59(1):61-81.
Blöcher R, Lamers C, Wittmann SK, Diehl O, Hanke, Merk D, Steinhilber D, Schubert-Zsilavecz M, Kahnt AS, Proschak E.
Med. Chem. Commun. 2016, 7: 1209-16.
Lamers C*, Merk D, Gabler M, Flesch D, Kaiser A, Schubert-Zsilavecz M.*corresponding author.
Future Med Chem. 2016;8(2):133-48.
Merk D*, Lamers C*, Weber J, Flesch D, Gabler M, Proschak E, Schubert-Zsilavecz M. *both authors contributed equally to this work.
Bioorg Med Chem. 2015 Feb 1;23(3):499-514.
Flesch D, Ness J, Lamers C, Dehm F, Popella S, Steri R, Ogorek I, Hieke M, Dannhardt G, Werz O, Weggen S, Schubert-Zsilavecz M.
Bioorg Med Chem Lett. 2015 Feb 15;25(4):841-6.
10) Revealing the macromolecular targets of complex natural products.
Reker D, Perna AM, Rodrigues T, Schneider P, Reutlinger M, Mönch B, Koeberle A, Lamers C, Gabler M, Steinmetz H, Müller R, Schubert-Zsilavecz M, Werz O, Schneider G.
Nat Chem. 2014 Dec;6(12):1072-8.
Merk D, Lamers C, Ahmad K, Carrasco Gomez R, Schneider G, Steinhilber D, Schubert-Zsilavecz M.
J Med Chem. 2014 Oct 9;57(19):8035-55.
Hanke T*, Lamers C*, Gomez RC, Schneider G, Werz O, Schubert-Zsilavecz M. *both authors contributed equally to this work.
Bioorg. Med. Chem. Lett. 2014 Aug 15;24(16):3757-63.
Lamers C, Dittrich M, Steri R, Proschak E, Schubert-Zsilavecz M:
Bioorg. Med. Chem. Lett. 2014 Aug 15;24(16):4048-52.
6) Medicinal chemistry and pharmacological potential of farnesoid X receptor (FXR) antagonists.
Lamers C, Schubert-Zsilavecz M, Merk D.
Curr Top Med Chem. 2014;14(19):2188-205.
5) Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
Merk D, Gabler M, Gomez RC, Flesch D, Hanke T, Kaiser A, Lamers C, Werz O, Schneider G, Schubert-Zsilavecz M:
Bioorg Med Chem. 2014 Apr 15;22(8):2447-60.
Lamers C, Flesch D, Schubert-Zsilavecz M, Merk D.
Expert Opin Ther Pat. 2013 Jan;23(1):47-77.
Flesch D, Merk D, Lamers C, Schubert-Zsilavecz M.
Expert Opin Ther Pat. 2013 Feb;23(2):233-67.
la Buscató E, Blöcher R, Lamers C, Klingler FM, Hahn S, Steinhilber D, Schubert-Zsilavecz M, Proschak E
J Med Chem. 2012 Dec 13;55(23):10771-5.
Lamers C, Schubert-Zsilavecz M, Merk D:
Expert Opin Ther Pat. 2012 Jul;22(7):803-41.
Book contributions
1) Arbeitsbuch Stöchiometrie: Chemisches Rechnen für Pharmazeuten und Chemiker, M. Wurglics, C. Lamers, D. Merk, 2nd edition, Govi Publisher, Eschborn 2019.
2) Arbeitsbuch Stöchiometrie: Chemisches Rechnen für Pharmazeuten und Chemiker, M. Wurglics, C. Lamers, D. Merk, 1st edition, Govi Publisher, Eschborn 2014.
3) Hunnius Pharmazeutisches Wörterbuch, H.P.T. Ammon, M. Schubert-Zsilavecz, C. Hunnius, 11th edition, De Gruyter Publisher 2014. Co-author of organic chemistry chapters.
Talks and poster presentations
15) Selected Talk:
Lamers C, Wagner B, Lambris J, Gros P, Ricklin D. Towards macrocyclic comlpement C3 inhibitor with prolonged target residence time - insights in structure-activity relationships and mode of action of compstatin.
2021 Frontiers in Medicinal Chemistry, online.
14) Selected Talk:
Lamers C, Wagner B, Lambris J, Gros P, Ricklin D. Mode of action of picomolar complement C3 inhibitor Cp40 - SAR and molecular insights.
2019 DPhG - annual meeting, Heidelberg, Germany
13) Poster (Prize winning):
Lamers C, Heinis C, Ricklin D. Development of peptides as therapeutics for pharmacological intervention in vital protein cascades.
2018 EFMC – International Symposium on Medicinal Chemistry, Ljubljana, Slovenia.
12) Short Talk and Poster (Prize winning):
Lamers C, Heinis C, Ricklin D. Development of peptides as therapeutics for pharmacological intervention in vital protein cascades.
2018 EFMC - Young Medicinal Chemist Symposium, Ljubljana, Slovenia.
11) Short Talk and Poster:
Lamers C, Wilbs J, Middendorp S, Heinis C. Development of bispecific bicyclic peptides. Annual Meeting of the German Pharmaceutical Society 2017, Saarbrücken, Germany.
10) Poster:
Lamers C, Heinis C. Development of bispecific bicyclic peptides.
Frontiers in Medicinal Chemistry 2017, Bern, Switzerland.
9) Poster:
Lamers C, Heinis C. Development of bispecific bicyclic peptides.
2016 EFMC - International Symposium on Medicinal Chemistry, Manchester, U.K.
8) Poster:
Lamers C, Heinis C. Development of bispecific bicyclic peptides.
2016 EFMC - Young Medicinal Chemist Symposium, Manchester, U.K.
7) Poster:
Lamers C, Merk D, Flesch D, Gabler M, Carrasco-Gomez R, Schneider G, Schubert-Zsilavecz M. Pyridinol/Pyridinon-Tautomerism determines activity at Farnesoid X Receptor: new agonistic and antagonistic ligands for FXR.
Annual Meeting of the German Pharmaceutical Society (DPhG) 2014, Frankfurt, Germany.
6) Poster:
Lamers C, Merk D, Flesch D, Gabler M, Carrasco-Gomez R, Schneider G, Schubert-Zsilavecz M. Pyridinol/Pyridinon-Tautomerism determines activity at Farnesoid X Receptor: new agonistic and antagonistic ligands for FXR.
2014 EFMC - International Symposium on Medicinal Chemistry, Lisbon, Portugal.
5) Talk:
Lamers C, Steri R, Proschak E, Schubert-Zsilavecz M. Interaction with Thr 279 improves activity of pirinixic acid derivatives at PPAR.
2nd International Summer School 2012. Chieti, Italy.
4) Poster:
Lamers C, Carrasco-Gomez R, Gabler M, Merk D, Steri R, Schneider G, Schubert-Zsilavecz M. Structure and ligand-based identification of novel synthetic ligands for Farnesoid X Receptor.
2012 EFMC - International Symposium on Medicinal Chemistry, Berlin, Germany.
3) Poster:
Lamers C, Steri R, Proschak E, Schubert-Zsilavecz M. Docking based development of new synthetic ligands for Farnesoid X Receptor. Annual Meeting of the German Pharmaceutical Society (DPhG) 2011 Innsbruck, Austria.
2) Short talk and Poster:
Lamers C, Steri R, Schubert-Zsilavecz M. SAR Studies of pirinixic acid derivatives as highly active dual PPARα/g agonists.
Doktorandentagung der DPhG 2011. Heringsdorf, Germany.
1) Poster:
Lamers C, Steri R, Schubert-Zsilavecz M. SAR Studies of pirinixic acid derivatives as highly active dual PPARα/g agonists.
2011 Frontiers in Medicinal Chemistry, Saarbrücken, Germany.